Japan’s Daiichi Sees Lower Earnings Impact Than Other M&As
This article was originally published in PharmAsia News
Unlike other Japanese drug makers who made major acquisitions this year, Daiichi Sankyo is expected to weather the usual damage to earnings reports, the firm says. Daiichi said it would purchase by next spring a greater than 50 percent of India's Ranbaxy Laboratories. Japanese competitors of Daiichi have experienced large drops in earnings in the wake of similar major acquisitions, such as Eisai's buy of MGI Pharma and Takeda Pharmaceutical's purchase of Millennium Pharmaceuticals. One reason Daiichi looks to come out on the positive end is its purchase of a generics maker with low research and development expenses. (Click here for more - a subscription may be required
You may also be interested in...
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.